Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 3/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558740 | 0.75 | DRD3 (0.39) | EPHX2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL19200493 | 0.73 | EPHX2 (0.37) | KDM1AEPHX2HTR2AHTR2CHTR2B | |
| SCHEMBL6629270 | 0.73 | EPHX2 (0.37) | KDM1AEPHX2HTR2AHTR2CHTR2B | |
| SCHEMBL19200258 | 0.73 | EPHX2 (0.37) | KDM1AEPHX2HTR2AHTR2CHTR2B | |
| SCHEMBL19182883 | 0.73 | EPHX2 (0.37) | KDM1AEPHX2HTR2AHTR2CHTR2B | |
| SCHEMBL6630657 | 0.72 | HTR2A (0.30) | HTR2A | |
| SCHEMBL17571679 | 0.71 | HTR2A (0.44) | KDM1ASIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL19200494 | 0.71 | HTR2A (0.44) | KDM1ASIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17571730 | 0.71 | HTR2A (0.44) | KDM1ASIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL28162183 | 0.71 | HTR2A (0.44) | KDM1ASIGMAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483271-B1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-7122567-B2 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | PYGL, GYS1, CBR3 | KDM1A 3691/4885EPHX2 2232/4885SIGMAR1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.